Screener
MoonLake Immunotherapeutics MLTX Net Change in Cash
Net Change in Cash at other companies
Other financials
Where this comes from
Reported directly by MoonLake Immunotherapeutics in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.
The source filing: MoonLake Immunotherapeutics’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 8:55 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001821586-26-000007
| (in thousands) | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Proceeds from options exercised under Employee Stock Option Plan | — | 100 |
| Net cash flow provided by financing activities | 30,644 | 73,122 |
| Effect of movements in exchange rates on cash held | (483) | (88) |
| Net change in cash and cash equivalents | (36,027) | 91,140 |
| Cash and cash equivalents, beginning of period | 334,517 | 180,426 |
| Cash and cash equivalents, end of period | $298,490 | $271,566 |
| Supplementary disclosure of cash flow information: | ||
| Cash paid for interest | $1,819 | — |
Item 1. Financial Statements (Unaudited)
FAQ
- What is MoonLake Immunotherapeutics's net change in cash?
- MoonLake Immunotherapeutics (MLTX) reported net change in cash of -$36.03M in Q1 2026.
- How has MoonLake Immunotherapeutics's net change in cash changed year-over-year?
- MoonLake Immunotherapeutics's net change in cash decreased by 139.5% year-over-year, from $91.14M to -$36.03M.
- What does net change in cash mean?
- Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.
Ask your AI about MoonLake Immunotherapeutics's net change in cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude